Team Hewins LLC Takes $381,000 Position in Novo Nordisk A/S (NYSE:NVO)

Team Hewins LLC purchased a new position in Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, Holdings Channel reports. The firm purchased 3,682 shares of the company’s stock, valued at approximately $381,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Westside Investment Management Inc. raised its holdings in shares of Novo Nordisk A/S by 83.3% during the 3rd quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock worth $130,000 after buying an additional 649 shares in the last quarter. Lazard Asset Management LLC boosted its stake in shares of Novo Nordisk A/S by 182.2% in the 3rd quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company’s stock valued at $135,883,000 after purchasing an additional 964,640 shares in the last quarter. Ieq Capital LLC grew its holdings in shares of Novo Nordisk A/S by 136.6% during the 3rd quarter. Ieq Capital LLC now owns 27,474 shares of the company’s stock valued at $2,498,000 after purchasing an additional 15,860 shares during the last quarter. One Capital Management LLC acquired a new position in Novo Nordisk A/S during the 3rd quarter worth approximately $203,000. Finally, Advisor Resource Council bought a new position in Novo Nordisk A/S in the 4th quarter valued at approximately $997,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 0.3 %

NYSE:NVO traded up $0.47 during trading hours on Friday, reaching $136.04. The company had a trading volume of 2,845,222 shares, compared to its average volume of 4,075,833. Novo Nordisk A/S has a twelve month low of $75.56 and a twelve month high of $138.28. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. The firm has a market cap of $610.48 billion, a price-to-earnings ratio of 46.91, a P/E/G ratio of 1.40 and a beta of 0.43. The business’s 50-day simple moving average is $128.21 and its two-hundred day simple moving average is $116.45.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.06. The business had revenue of $9.52 billion for the quarter, compared to analysts’ expectations of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. On average, equities analysts expect that Novo Nordisk A/S will post 3.43 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on NVO. BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.